Alkem Laboratories has reported results for fourth quarter (Q4) and year ended March 31, 2023
The company has reported over three-fold jump in its net profit at Rs 254.79 crore for the quarter under review as compared to Rs 76.88 crore for the same quarter in the previous year. Total income of the company increased by 12.33% at Rs 2,314.59 crore for Q4FY23 as compared to Rs 2,060.54 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 37.45% fall in its net profit at Rs 67.68 crore for fourth quarter ended March 31, 2023 as compared to Rs 108.21 crore for the same quarter in the previous year. However, total income of the company increased by 18.64% at Rs 2,971.27 crore for Q4FY23 as compared to Rs 2,504.38 crore for the corresponding quarter previous year.
For the year ended March 31, 2023, the company has reported 26.39% fall in its net profit at Rs 1,134.47 crore as compared to Rs 1,541.25 crore for the previous year. However, total income of the company increased by 3.22% at Rs 9,320.84 crore for year under review as compared to Rs 9,029.70 crore for year ended March 31, 2022.
For the year ended March 31, 2023, on the consolidated basis, the company has reported 40.08% fall in its net profit at Rs 1,006.81 crore as compared to Rs 1,680.32 crore for the previous year. However, total income of the company increased by 9.43% at Rs 11,815.34 crore for year under review as compared to Rs 10,796.84 crore for year ended March 31, 2022.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1504.25 |
Dr. Reddys Lab | 6263.70 |
Cipla | 1406.25 |
Zydus Lifesciences | 948.20 |
Lupin | 1615.85 |
View more.. |